posted on 2018-04-19, 00:00authored byAbhik Mallick, Meenu Mahesh Kuman, Arijit Ghosh, Benu Brata Das, Sudipta Basu
The
mitochondrion is an unorthodox target for developing chemotherapeutic
strategies for cancer. Mitochondrion also contains circular DNA responsible
for the protein synthesis for oxidative phosphorylation. Damaging
mitochondrial DNA selectively, keeping nuclear DNA intact is currently
a foremost hurdle. Here, triphenylphosphine-decorated mitochondria
targeting positively charged Cerberus Nanoparticle (mt-CN) was engineered.
These nanoparticles can contain cisplatin (DNA damaging agent) and
SN38 or Topotecan (Topoisomerase I inhibitor) simultaneously in a
single particle. Confocal laser scanning microscopy confirmed the
homing of the mt-CNs into mitochondria in MCF7 breast cancer cells.
We further confirmed mt-CN-mediated marked accumulation of mt-DNA
damage in MCF7 cells using a combination of long-range polymerase-chain-reaction and gel electrophoresis.
MCF7 cells treated with mt-CN exhibited a significant reduction in
synthesis of mitochondria-encoded cytochrome c oxidase subunit 1 while
keeping nuclear DNA unperturbed. The mt-CN damaged mitochondrial outer
membrane, which leads to the release of cytochrome c and reactive
oxygen species generation. Finally, mt-CNs induced apoptosis in MCF7
cells by cleavage of caspase-9 to trigger improved cell death. It
can be anticipated that these Cerberus Nanoparticles can inhibit various
targets specifically and spatially into mitochondria as next-generation
chemotherapy.